Karnofsky award recognizes 'outstanding achievements' in cancer
research
PHOENIX, Ariz. - April 1, 2010 - Dr. Daniel D. Von Hoff,
Physician-in-Chief for the Translational Genomics Research
Institute (TGen), has won a top award from the American Society of
Clinical Oncology (ASCO) for his cancer research.
Dr. Von Hoff, M.D., F.A.C.P., will receive the 2010 David A.
Karnofsky Memorial Award and Lecture at ASCO's 46th Annual Meeting,
June 4-8 at the McCormick Place in Chicago.
ASCO will present the award to Dr. Von Hoff "for his outstanding
achievements in cancer research and for his impact on the treatment
of patients with cancer."
Dr. Von Hoff is an internationally recognized physician-scientist
who has contributed to the development of numerous anticancer
agents, including paclitaxel, docetaxel, irinotecan and
gemcitabine. He also is the Chief Scientific Officer of TGen
Clinical Research Services at Scottsdale Healthcare and at US
Oncology, and is a Clinical Professor of Medicine at the University
of Arizona College of Medicine.
Each year through its Special Awards Program, ASCO recognizes
quality researchers, patient advocates and leaders of the global
oncology community who through their work have made significant
contributions to enhancing cancer care. These recipients of ASCO's
highest, most prestigious awards collectively represent significant
strides in cancer treatment and leadership in the oncology
community.
"The work of this year's awardees collectively represents decades
of commitment to improving the care and quality of life for people
living with cancer," said Richard L. Schilsky, M.D., ASCO's
Immediate Past President and Chair of the Special Awards Selection
Committee. "Our understanding of the biological basis of cancer and
our ability to transform that knowledge into better treatments for
patients have been enhanced by their contributions and it is an
honor to present them ASCO's highest awards."
The David A. Karnofsky Memorial Award was first presented in 1970.
It recognizes outstanding contributions to cancer research,
diagnosis and/or treatment. A lecture is given during the opening
session of the ASCO Annual Meeting.
The award is named after David A. Karnofsky, 1914-1969, an American
clinical oncologist and specialist in cancer chemotherapy who was
affiliated with the Memorial Sloan-Kettering Cancer Center. He is
known for developing the Karnofsky scale, an index for determining
a patient's suitability for therapy and for estimating a patient's
physical state, performance and prognosis after a therapeutic
procedure.
*
About the American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) is the world's
leading professional organization representing physicians who care
for people with cancer. With more than 28,000 members, ASCO is
committed to improving cancer care through scientific meetings,
educational programs and peer-reviewed journals. For ASCO
information and resources, visit www.asco.org/presscenter.
Patient-oriented cancer information is available at
www.cancer.net.
*
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix,
Arizona-based non-profit organization dedicated to conducting
groundbreaking research with life changing results. Research at
TGen is focused on helping patients with diseases such as cancer,
neurological disorders and diabetes. TGen is on the cutting edge of
translational research where investigators are able to unravel the
genetic components of common and complex diseases. Working with
collaborators in the scientific and medical communities, TGen
believes it can make a substantial contribution to the efficiency
and effectiveness of the translational process. TGen is affiliated
with the Van Andel Research Institute in Grand Rapids, Michigan.
For more information, visit: www.tgen.org.
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]
# # #